Newly Diagnosed T1DM With Dka In Major β-Thalassemia Patient During Covid-19 Infection
DOI:
https://doi.org/10.52783/jns.v14.2591Keywords:
COVID-19, Type 1 Diabetes Mellitus, Diabetic Ketoacidosis, β-Thalassemia Major, Iron Overload, Insulin Resistance, Transfusion-Related Acute Lung Injury (TRALI)Abstract
The COVID-19 pandemic has significantly impacted global public health, with diabetes mellitus (DM) being a key factor associated with adverse clinical outcomes. This case report discusses a 20-year-old male diagnosed with major β-thalassemia who developed newly diagnosed type 1 diabetes mellitus (T1DM) with diabetic ketoacidosis (DKA) during COVID-19 infection. Thalassemia patients are at increased risk for iron overload, which contributes to β-cell dysfunction and insulin resistance, leading to diabetes. This patient had persistent hyperglycemia, recurrent DKA, and was classified as idiopathic T1DM due to negative autoantibodies and low C-peptide levels. The case highlights the complex interplay between iron overload, β-cell dysfunction, and hyperglycemia in thalassemia patients, compounded by COVID-19 infection. Despite intensive management, including insulin therapy, fluid resuscitation, and iron chelation therapy, the patient succumbed to transfusion-related acute lung injury (TRALI). This case underscores the need for early detection of diabetes in thalassemia patients and emphasizes the importance of optimizing iron chelation therapy to reduce metabolic complications.
Downloads
Metrics
References
Alhumaid, S. et al. .2021. Diabetic ketoacidosis in patients with SARS-CoV-2: a systematic review and meta-analysis, Diabetology and Metabolic Syndrome. BioMed Central, 13(1), pp. 1–22.
Ang AL, Tzoulis P, Prescott E, Davis BA, Barnard M, Shah FT. 2014. History of myocardial iron loading is a strong risk factor for diabetes mellitus and hypogonadism in adults with βthalassemia major. Eur J Haematol;92:229-236.
Armeni E, Aziz U, Qamar S, et al. 2020. Protracted ketonaemia in hyperglycaemic emergencies in COVID-19: a retrospective case series. Lancet Diabetes Endocrinol 2020;8:660–663
Atmakusuma, D and Setyaningsih, I. (2014). Dasar-Dasar Thalassemia: Salah Satu Jenis Hemoglobinopati. In Setiati, S et al. (eds.) Buku Ajar Ilmu Penyakit Dalam. VI. Jakarta: Interna Publishing, pp. 2623-2631.
Brandstaetter, E. et al. 2019. Recurrent diabetic ketoacidosis, Archives of Endocrinology and Metabolism, 63(5), pp. 153–535.
Burhan, E. et al. 2022. Pedoman tatalaksana COVID-19 edisi 4.
de Sanctis, V., Soliman, A. T., Elsedfy, H., Yaarubi, S. A., Skordis, N., Khater, D., El Kholy, M., Stoeva, I., Fiscina, B., Angastiniotis, M., Daar, S., & Kattamis, C. 2016. The ICET-A Recommendations for the Diagnosis and Management of Disturbances of Glucose Homeostasis in Thalassemia Major Patients. Mediterranean journal of hematology and infectious diseases, 8(1), e2016058.
de Sanctis, V. et al. 2021. Pancreatic changes affecting glucose homeostasis in transfusion dependent β-thalassemia (TDT): A short review, Acta Biomedica, 92(3).
ElSayed, et al. 2022. 2. Classification and Diagnosis of Diabetes: Standards of Care in Diabetes—2023. Diabetes Care.
Karimi, M. et al. 2008. Prevalence of diabetic ketoacidosis (DKA) in thalassemia major patients in Iran due to secondary iron overload, Rivista Italiana di Medicina dell’Adolescenza, 6(1), pp. 47–51.
Kemenkes, 2018. Pedoman Nasional Pelayanan Kedokteran Tata Laksana Thalasemia
Khunti, K. et al. 2021. New-Onset Diabetes, 44(December), pp. 2645–2655.
Kitabchi, A. E. et al. 2009. Hyperglycemic crises in adult patients with diabetes, Diabetes Care, 32(7), pp. 1335–1343.
Farmakis, D et al. 2022. 2021 Thalassaemia International Federation Guidelines for the Management of Transfusion-dependent Thalassemia. HemaSphere.
Holt, et al. 2021. The management of Type 1 Diabetes in Adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia.
Li, H. et al. 2020. Newly diagnosed diabetes is associated with a higher risk of mortality than known diabetes in hospitalized patients with COVID-19, Diabetes, Obesity and Metabolism, 22(10), pp. 1897–1906.
Patel, S. K.; Ma, C. S.; Fourlanos, S. & Greenfield, J. R. 2021. Autoantibody-Negative Type 1 Diabetes: A Neglected Subtype. Trends in Endocrinology & Metabolism.
PERKENI. 2021. Pedoman Petunjuk Praktis Terapi Insulin Pada Pasien Diabetes Mellitus 2021, Pb Perkeni, pp. 42–46.
Sahu, S., Hemlata and Verma, A. 2014. Adverse events related to blood transfusion’, Indian Journal of Anaesthesia, 58(5), pp. 543–551.
Shrestha, D. B., Budhathoki, P., Raut, S., Adhikari, S., Ghimire, P., Thapaliya, S., Rabaan, A. A., & Karki, B. J. 2021. New-onset diabetes in COVID-19 and clinical outcomes: A systematic review and meta-analysis. World journal of virology, 10(5), 275–287.
Tjokroprawiro, A. and Murtiwi, S. 2015. Kegawatdaruratan Diabetes Mellitus dalam Askandar, T., Poernomo, B. S., Chairul, E., Djoko, S., dan Gatot, S. Buku Ajar Ilmu Penyakit Dalam. Edisi ke-2. Surabaya: Airlangga University Press, 118-125.
Tjokroprawiro, A., 2017. Formula Klinis Praktis Bidang Diabetologi - Endokrinologi - Metabolisme, 5th ed. Pusat Diabetes dan Nutrisi Surabaya (PDNS), Surabaya.
Unsworth, R. et al. 2020. New-onset type 1 diabetes in children during COVID-19: Multicenter regional findings in the U.K., Diabetes Care, 43(11), pp. e170–e171.
WHO. 2023. WHO Coronavirus (COVID-19) Dashboard. Geneva: World Health Organization.
Yonekawa, A. and Shimono, N. 2022. Clinical Significance of COVID-19 and Diabetes: In the Pandemic Situation of SARS-CoV-2 Variants Including Omicron (B.1.1.529), Biology, 11(3), pp. 1–18.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
